Clinical Trial Update: Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention [Phase 2]

View source ↗

Summary

Phase 2 randomized, open-label trial evaluating dabigatran etexilate in patients undergoing elective percutaneous coronary intervention; results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Dabigatran etexilate (Dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Heart Catheterization | Phase 2 | Status: COMPLETED | Results posted: 2011-10-25